Abstract
Objective To investigate the correlations of serum cystatin C level with severity of stroke and short-term outcome in patients with acute ischemic stroke. Methods Patients with first-ever acute ischemic stroke aged ≥50 years who did not receive thrombolysis and took a visit within 3 d after onset were selected prospectively. The serum cystatin C level was detected within 24 h after admission and various clinical data were collected. The National Institutes of Health Stroke Scale (NIHSS) was used to assess the neurological deficits on the day of admission. The NIHSS score 2 was defined as poor outcome. Results A total of 188 patients were enrolled, including 93 (49.5%) females and 95 (50.5%) males, their mean age was 65.4±9.2 years old (range 50-87). There were 120 patients with mild stroke (63.8%), 68 with moderate to severe stroke (36.2%); 106 patients (56.4%) had good outcome and 82 (43.6%) had poor outcome. Univariate analysis showed that serum cystatin C level in the moderate to severe stroke group was significantly higher than that in the mild stroke group (1.36±0.29 mg/L vs. 1.21±0.23 mg/L; t=3.902, P<0.001), the serum cystatin C level in the poor outcome group was significantly higher than that in the good outcome group (1.38±0.25 mg/L vs. 1.22±0.25 mg/L; t=4.101, P=0.001). Multivariate logistic regression analysis showed that the serum cystatin C level was an independent risk factor for stroke severity (odds ratio 12.182, 95% confidence interval 11.163-13.202; P<0.001) and short-term poor outcome (odds ratio 9.025, 95% confidence interval 8.202-9.848; P<0.001). Conclusion The serum cystatin C level is significantly correlated with the severity of stroke and the short-term outcome in patients with acute ischemic stroke. Key words: Stroke; Brain Ischemia; Cystatin C; Severity of Illness Index; Treatment Outcome; Risk Factors; Biomarkers
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call